Weiss Multi-Strategy Advisers’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-104	Closed	-$12K	–	514
2016 Q2	$12K	Sell	104 -86	-45%	-$9.53K	﹤0.01%	396
2016 Q1	$22K	Hold	190	–	–	﹤0.01%	456
2015 Q4	$36K	Sell	190 -3	-2%	-$561	﹤0.01%	379
2015 Q3	$33K	Sell	193 -74	-28%	-$26.7K	﹤0.01%	385
2015 Q2	$169K	Buy	267 +2	+0.8%	+$1.06K	0.01%	417
2015 Q1	$136K	Buy	265 +27	+11%	+$13.6K	0.01%	412
2014 Q4	$128K	Buy	+238	New	+$107K	﹤0.01%	388

Other funds holding VIRX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Weiss Multi-Strategy Advisers's VIRX Position: Q3 2016 in Review

Weiss Multi-Strategy Advisers sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2016, closing a stake of 104 shares — an estimated $12K sold.

Weiss Multi-Strategy Advisers first reported a position in VIRX in Q4 2014 and held it in 7 quarters. The position peaked at $169K in Q2 2015. 40 funds tracked by Wall St. Rank hold VIRX as of Q3 2016.

Weiss Multi-Strategy Advisers reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 104 Viracta Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $12K.
Weiss Multi-Strategy Advisers first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 7 quarters.
Weiss Multi-Strategy Advisers's Viracta Therapeutics, Inc. Common Stock position peaked at $169K in Q2 2015.
40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2016, filed 14 Nov 2016.